JPY4,297.00
0.54% yesterday
Tokyo, Jun 06, 08:08 am CET
ISIN
JP3463000004
Symbol
4502
Index
Sector
Industry

Takeda Pharmaceutical Target price 2025 - Analyst rating & recommendation

Takeda Pharmaceutical Classifications & Recommendation:

Buy
50%
Hold
50%

Takeda Pharmaceutical Price Target

Target Price JPY4,956.21
Price JPY4,295.00
Potential
Number of Estimates 14
14 Analysts have issued a price target Takeda Pharmaceutical 2026 . The average Takeda Pharmaceutical target price is JPY4,956.21. This is higher than the current stock price. The highest price target is
JPY5,800.00 35.04%
register free of charge
, the lowest is
JPY4,500.00 4.77%
register free of charge
.
A rating was issued by 16 analysts: 8 Analysts recommend Takeda Pharmaceutical to buy, 8 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Takeda Pharmaceutical stock has an average upside potential 2026 of . Most analysts recommend the Takeda Pharmaceutical stock at Buy or hold.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Billion JPY 4,581.55 4,564.71
7.45% 0.37%
EBITDA Margin 21.52% 27.31%
3.66% 26.92%
Net Margin 2.36% 5.79%
30.28% 145.79%

14 Analysts have issued a sales forecast Takeda Pharmaceutical 2026 . The average Takeda Pharmaceutical sales estimate is

JPY4.6t
Unlock
. This is
0.37% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
JPY4.7t 2.83%
Unlock
, the lowest is
JPY4.5t 2.74%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 JPY4.6t 7.45%
2026
JPY4.6t 0.37%
Unlock
2027
JPY4.6t 0.91%
Unlock
2028
JPY4.7t 2.38%
Unlock
2029
JPY4.9t 3.55%
Unlock
2030
JPY4.9t 0.74%
Unlock

8 Analysts have issued an Takeda Pharmaceutical EBITDA forecast 2026. The average Takeda Pharmaceutical EBITDA estimate is

JPY1.2t
Unlock
. This is
30.19% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
JPY1.4t 46.97%
Unlock
, the lowest is
JPY1.1t 19.11%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 JPY986b 3.52%
2026
JPY1.2t 26.43%
Unlock
2027
JPY1.3t 1.06%
Unlock
2028
JPY1.3t 3.63%
Unlock
2029
JPY1.2t 8.78%
Unlock
2030
JPY1.1t 3.59%
Unlock

EBITDA Margin

2025 21.52% 3.66%
2026
27.31% 26.92%
Unlock
2027
27.35% 0.15%
Unlock
2028
27.68% 1.21%
Unlock
2029
24.38% 11.92%
Unlock
2030
23.34% 4.27%
Unlock

7 Takeda Pharmaceutical Analysts have issued a net profit forecast 2026. The average Takeda Pharmaceutical net profit estimate is

JPY264b
Unlock
. This is
144.75% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
JPY325b 201.57%
Unlock
, the lowest is
JPY227b 109.96%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 JPY108b 25.08%
2026
JPY264b 144.75%
Unlock
2027
JPY298b 12.95%
Unlock
2028
JPY318b 6.69%
Unlock
2029
JPY349b 9.56%
Unlock

Net Margin

2025 2.36% 30.28%
2026
5.79% 145.79%
Unlock
2027
6.48% 11.92%
Unlock
2028
6.75% 4.17%
Unlock
2029
7.14% 5.78%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share JPY 68.35 167.86
25.78% 145.59%
P/E 25.59
EV/Sales 2.38

7 Analysts have issued a Takeda Pharmaceutical forecast for earnings per share. The average Takeda Pharmaceutical EPS is

JPY167.86
Unlock
. This is
145.66% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
JPY206.83 202.69%
Unlock
, the lowest is
JPY144.00 110.74%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 JPY68.35 25.78%
2026
JPY167.86 145.59%
Unlock
2027
JPY189.60 12.95%
Unlock
2028
JPY202.29 6.69%
Unlock
2029
JPY221.63 9.56%
Unlock

P/E ratio

Current 62.86 38.34%
2026
25.59 59.29%
Unlock
2027
22.65 11.49%
Unlock
2028
21.23 6.27%
Unlock
2029
19.38 8.71%
Unlock

Based on analysts' sales estimates for 2026, the Takeda Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.38 7.39%
2026
2.38 0.18%
Unlock
2027
2.36 0.90%
Unlock
2028
2.31 2.33%
Unlock
2029
2.23 3.43%
Unlock
2030
2.21 0.74%
Unlock

P/S ratio

Current 1.48 4.53%
2026
1.48 0.37%
Unlock
2027
1.47 0.90%
Unlock
2028
1.44 2.33%
Unlock
2029
1.39 3.43%
Unlock
2030
1.38 0.73%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today